Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14461324 | 0.93 | BACE1 (0.43) | BACE1MAPK1CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL25417788 | 0.87 | BACE1 (0.36) | BACE1DPP4CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL29498916 | 0.86 | BACE1 (0.42) | BACE1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL359522 | 0.85 | BACE1 (0.40) | BACE1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL14630717 | 0.85 | BACE1 (0.40) | BACE1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL14630715 | 0.85 | BACE1 (0.40) | BACE1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL4797973 | 0.85 | BACE1 (0.40) | BACE1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL241741 | 0.85 | BACE1 (0.40) | BACE1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL14840794 | 0.85 | BACE1 (0.40) | BACE1CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL26663762 | 0.85 | BACE1 (0.40) | BACE1CYP3A4HTTSMN1; SMN2SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10233156-B2 | 9-membered fused ring derivative | SHIONOGI & CO., LTD. (JP) | 2019-03-19 | — | — | US | disclosed |
| US-20180079727-A1 | 9-MEMBERED FUSED RING DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079727-A1 | 9-MEMBERED FUSED RING DERIVATIVE | ACSS2, AGTR2, ACSL3 | BACE1 1435/4885DPP4 3206/4885ADORA3 763/4885 |
| US-10233156-B2 | 9-membered fused ring derivative | AGTR2, ACSS2, ACSL3 | BACE1 1632/4885DPP4 2869/4885ADORA3 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.